Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Orexo AB (OTC: ORXOY).

Full DD Report for ORXOY

You must become a subscriber to view this report.


Recent News from (OTC: ORXOY)

Orexo AB ADR 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Orexo AB ADR in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: July, 11 2018 13:07
Orexo AB jumps 18.1% post Q2 results
Orexo AB ( OTCQX:ORXOY +18.1% )  reports Q2  revenue growth of 25.5% Y/Y to SEK 199.7M. More news on: Orexo AB ADR, Orexo AB, Read more ...
Source: SeekingAlpha
Date: July, 11 2018 12:30
Orexo AB ADR reports Q2 results
Orexo AB ADR ( OTCQX:ORXOY ): Q2 EPS of SEK1.45. More news on: Orexo AB ADR, Orexo AB, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: July, 11 2018 05:43
Orexo: Interim Report Q2 2018
UPPSALA, Sweden , July 11, 2018 /PRNewswire/  -- Q2 2018 highlights Total net revenues of SEK 199.7 million (159.1), up 25.5 percent from Q2 previous year Zubsolv US net revenue of SEK 158.4 million (124.1), up 27.6 percent in SEK and 29.8 percent in local currency compare...
Source: PR Newswire
Date: July, 11 2018 02:43
Zubsolv® Now Launched in the EU, Which Triggers a EUR 3m Milestone Payment to Orexo
UPPSALA, Sweden , June 18, 2018 /PRNewswire/ -- Orexo AB today announces that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the EU. The launch is triggering a milestone paymen...
Source: PR Newswire
Date: June, 18 2018 12:38
Zubsolv® Now Launched in the EU, Which Triggers a EUR 3M Milestone Payment to Orexo
UPPSALA, Sweden , June 18, 2018 /PRNewswire/ -- Orexo AB today announces that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the EU. The launch is triggering a milestone payment ...
Source: PR Newswire
Date: June, 18 2018 02:18
Orexo´s CFO Resigns and Will Leave the Company in November 2018
UPPASALA, Sweden , May 31, 2018 /PRNewswire/ -- Orexo AB today announces that Henrik Juuel has notified the company of his resignation after working for five years as the company´s Chief Financial Officer. Henrik Juuel will have his last working day with Orexo in November, before he ...
Source: PR Newswire
Date: May, 31 2018 02:56
Orexo AB ADR 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Orexo AB ADR in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: April, 26 2018 14:21
Orexo - Interim Report Q1 2018
UPPSALA, Sweden , April 26, 2016 /PRNewswire/ -- Q1 2018 highlights Total net revenues of SEK 139.7 million , up 9.7 percent from Q1 previous year Zubsolv US net revenue of SEK 131.1 million , up 14.9 percent in SEK and 26.2 percent in local currency compared to the same...
Source: PR Newswire
Date: April, 26 2018 02:19
Report from Orexo AB's Annual General Meeting
UPPSALA, Sweden , April 12, 2018 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 12 April 2018 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be seven with no ...
Source: PR Newswire
Date: April, 12 2018 12:24

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-18N/A6.00N/AN/A0
2018-12-17N/A6.00N/AN/A0
2018-12-14N/A6.00N/AN/A0
2018-12-13N/A6.00N/AN/A0
2018-12-12N/A6.00N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-19207526.6667Cover
2018-11-067070100.0000Short
2018-10-29200200100.0000Short
2018-10-197575100.0000Short
2018-10-0120040050.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ORXOY.


About Orexo AB (OTC: ORXOY)

Logo for Orexo AB (OTC: ORXOY)

lt p gt Orexo is a specialty pharma company with commercial operations in the United States and R amp amp D in Sweden developing improved treatments using proprietary drug delivery technology. The company s product, Zubsolv buprenorphine and naloxone , for maintenance launched in the United States in September . lt /p gt

 

Contact Information

 

 

Current Management

  • Nikolaj Sorensen / CEO
  • Robert A. DeLuca / President, Subsidiary
  • Henrik Juuel / EVP, CFO
  • Martin Nicklasson / Chairman
  • David Colpman /
  • Raymond G. Hill /
  • Staffan Lindstrand /
  • Kristina Schauman /
  • Michael Shalmi /

Current Share Structure

  • Market Cap: $161,990,654 - 03/14/2018
  • Issue and Outstanding: 34,539,585 - 06/30/2017

 


Recent Filings from (OTC: ORXOY)

Quarterly Report - Orexo Full Year Report incl. Q4 2017
Filing Type: Quarterly Report - Orexo Full Year Report incl. Q4 2017Filing Source: OTC Markets
Filing Date: February, 01 2018
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: October, 19 2017

 

 


Daily Technical Chart for (OTC: ORXOY)

Daily Technical Chart for (OTC: ORXOY)


Stay tuned for daily updates and more on (OTC: ORXOY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ORXOY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ORXOY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ORXOY and does not buy, sell, or trade any shares of ORXOY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/